Gene Therapy R&D and Revenue Forecasts 2020-2030

Gene Therapy R&D and Revenue Forecasts 2020-2030

The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the cancer treatment submarket accounted for 55.8% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the first half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 215-page report you will receive 157 charts– all unavailable elsewhere.

The 215-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Gene Therapy market forecasts from 2020-2030
  • This report assesses the approved gene therapy products in the market and gives revenue to 2030
  • Provides qualitative analysis and forecast of the submarket by indication for the period 2020-2030:
  • Cancer
  • Cardiovascular disorders
  • Rare diseases
  • Ophthalmological diseases
  • Infectious Diseases
  • Neurological Disorders
  • Diabetes Mellitus
  • Other therapeutic uses
  • Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
  • UniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics
  • Applied Genetics Technologies Corporation
  • Oxford Biomedica
  • GenSight Biologics
  • & Other Companies
  • Assesses the outlook for the leading gene treatment R&D pipeline for 2019 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for four leading agents:
  • Collategene (AMG0001, AnGes MG/Vical)
  • BC-819 (BioCancell)
  • BC-821 – BioCancell
  • SPK-CHM – Spark Therapeutics
  • SPK-FIX – Spark Therapeutics/Pfizer
  • SPK-TPP1- Spark Therapeutics
  • Lenti-D (Bluebird Bio)
  • LentiGlobin (Bluebird Bio)
  • VM202-DPN – ViroMed
  • Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2020 to 2030. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.
  • Our study discusses factors that influence the market including these:
  • Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
  • Genomic editing technology and other supporting components
  • Collaborations to develop and launch gene-based products – acquisitions and licensing deals
  • Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
  • Gene therapies for ophthalmologic diseases – next-generation medicines
  • Regulations in the United States, the European Union and Japan – overcoming technological and medical challenges to pass clinical trials.
Visiongain’s study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Gene Therapy Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Gene Therapy
2.1 What is Gene Therapy?
2.2 Types of Gene Therapy
2.3 Products Excluded from the Report
2.4 Gene Therapy Vectors
3. Gene Therapy World Market: Leading Treatments and Forecasts, 2017-2028
3.1 The World Market for Gene Therapy: Overview of Products
3.2 Luxturna
3.3 Kymriah
3.4 Yescarta
3.5 Zolgensma
3.6 Gendicine (rAd-p53) – The First Gene Therapy to Market
3.7 Oncorine: Growth is Hindered by Certain Factors
3.8 Neovasculgen: Russia’s First Gene Therapy
3.8.1 Neovasculgen: Historical Performance and Revenue Forecast, 2019-2030
3.9 Strimvelis: Second Gene Therapy for an Inherited Disease Ever to be approved for Sale and the First Corrective Gene Therapy for Children to be Approved Anywhere in the World
3.10 Glybera
4. Gene Therapy World Market: By Vector and Forecasts, 2020-2030
4.1 Viral Vectors
4.1.1 Retroviruses
4.1.2 Lentiviruses
4.1.3 Adenoviruses
4.1.4 Adeno Associated Virus
4.1.5 Herpes Simplex Virus
4.1.6 Poxvirus
4.1.7 Vaccinia Virus
4.2 Non-Viral Vector
4.2.1 Naked/Plasmid Vectors
4.2.2 Gene Gun
4.2.3 Electroporation
4.2.4 Lipofection
5. Gene Therapy World Market and Disease Submarkets, 2019-2030
5.1 The Global Market for Gene Therapy Drug Treatments in 2019
5.2 Gene Therapy Market Forecast, 2019-2030
5.3 Gene Therapy for Cancer
5.3.1 Clinical Trials for Cancer
5.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2019-2030
5.4 Gene Therapy for Rare Diseases
5.4.1 The Rare Disease Treatment Submarket Forecast 2019-2030
5.5 Gene Therapy for Cardiovascular Diseases
5.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2019-2030
5.6 Gene Therapy for Ophthalmologic Diseases
5.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases
5.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2019-2030
5.7 Gene Therapy for Infectious Diseases
5.7.1 Infectious Diseases Submarket Forecast 2019-2030
5.8 Gene Therapy for Neurological Disorders
5.8.1 Neurological Disorders Submarket Forecast 2019-2030
5.9 Gene Therapy for Diabetes Mellitus
5.9.1 Diabetes Mellitus Submarket Forecast 2019-2030
5.10 Gene Therapy for Other Diseases
5.10.1 The Other Disease Treatment Submarket Forecast 2019-2030
5.10.2 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader
6. Gene Therapy World Market: by Region Forecasts, 2020-2030
6.1 Leading Regional Markets of Gene Therapy 2019-2030
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 MEA
7. R&D Pipeline Analysis and Forecasts, 2019-2030
7.1 Pipeline
7.2 Pipeline Analysis
7.3 Collategene (AMG0001) - AnGes MG/Vical
7.4 BC-819 - BioCancell
7.5 BC-821 - BioCancell
7.6 Lenti-D - Bluebird Bio
7.7 LentiGlobin (LentiGlobin BB305) - Bluebird Bio
7.8 SPK-CHM - Spark Therapeutics
7.9 SPK-FIX - Spark Therapeutics/Pfizer
7.10 SPK-TPP1- Spark Therapeutics
7.11 VM202-DPN - ViroMed
7.12 Important Pipeline Technology Developments
7.13 Clustered regularly interspaced short palindromic repeats (CRISPR)
7.14 The Future of the Gene Therapy Pipeline
8. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future
8.1 UniQure B. V. - the First Commercial Stage Gene Therapy Company in the West
8.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies
8.2.1 Biogen: Financial Performance 2015-2018
8.2.2 Biogen: Key News
8.3 Bluebird Bio: Gene Editing Technology
8.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
8.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
8.6 Oxford Biomedica: Collaboration as a Strategy
8.7 GenSight Biologics - Novel Mitochondrial Technology Platform
8.8 Celgene Corporation
8.8.1 Celgene Corporation: Financial Overview
8.9 GlaxoSmithKline plc.
8.9.1 GlaxoSmithKline plc: Financial Overview
8.9.2 GlaxoSmithKline plc: Recent Transactions Summary
8.10 Takeda Pharmaceuticals
8.10.1 Takeda Pharmaceuticals: Financial Overview
8.10.2 Takeda Pharmaceuticals: Key News
8.11 Cellectis
8.11.1 Cellectis: Key News
8.12 Sangamo Therapeutics, Inc.
8.12.1 Sangamo Therapeutics, Inc: Key News
8.13 REGENXBIO Inc.
8.13.1 REGENXBIO Inc.: Key News
8.14 Voyager Therapeutics
8.14.1 Voyager Therapeutics: Key News
8.15 Bristol Myers Squibb
8.15.1 Bristol-Myers Squibb Company: Financial Overview
8.15.2 Bristol-Myers Squibb Company: Recent Transactions Summary
8.16 Genzyme Corporation
8.16.1 Genzyme Corporation: Key News
8.17 Chiesi Farmaceutici S.p.A
8.17.1 Chiesi Farmaceutici S.p.A: Key News
8.18 Benitec BioPharma
8.18.1 Benitec BioPharma: Key News
8.19 Gene Therapy and Big Pharma: Collaborations
9. Research Interviews
9.1 Kyriacos Mitrophanous, Chief Scientific Officer at Oxford Biomedica
9.1.1 Oxford Biomedica
9.1.2 Gene therapy landscape
9.1.3 Oxford Biomedica LentiVector ®
9.1.4 Pricing and Next Steps in Gene Therapy
9.2 Professor Dusko Ilic, Professor of Stem Cell Science, King's College London
9.2.1 Gene therapy landscape
9.2.2 Ethical Considerations with Gene Therapy
9.2.3 Regulation & Pricing of Gene Therapy Products
10. Qualitative Analysis of the Gene Therapy Market, 2020-2030
10.1 SWOT Analysis of the Gene Therapy Treatment Market, 2020
10.2 Strengths: A Vast Pipeline for a Wide Range of Indications
10.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
10.4 Opportunities and Threats for the Gene Therapy Drug Market, 2020-2030
10.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way
10.6 Threats: Expensive Drugs with Strict Regulations
10.7 Regional markets: Regulation of the Gene Therapy Market
10.7.1 Gene Therapy Regulations: Evolving with the Market
10.7.2 US Regulations: Strict Regulation of a Cautious Market
10.7.3 EU Regulations: One Approval So Far
10.7.4 Japanese Regulations: A Rigorous Process
10.7.5 China Has Highest Gene Sequencing Capacity
11. Conclusions
11.1 The World Gene Therapy Treatment Market: Current World Outlook
11.1.1 Driver for Growth to 2030: A Vast Pipeline of Gene Therapy Products
11.1.2 Leading Gene Therapy Treatment Submarkets and Products, 2019-2030
11.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success
11.2 The Future of the Gene Therapy Treatment Market
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 3.1 Approved Gene Therapies, 2019
Table 3.2 Luxturna Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.3 Kymriah Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.4 Yescarta Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.5 Zolgensma Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.6 Gendicine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.7 Gene Therapies in Pipeline, 2019
Table 3.8 Oncorine Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.9 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2014-2018
Table 3.10 Neovasculgen Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.11 Strimvelis Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.1 Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.2 Retroviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.3 Lentiviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.4 Adenoviruses Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.5 Adeno Associated Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.6 Herpes Simplex Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.7 Poxvirus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.8 Vaccinia Virus Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.9 Non-Viral Vector Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.10 Naked/Plasmid Vectors Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.11 Gene Gun Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.12 Electroporation Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.13 Lipofection Market Forecast, Revenue ($bn), AGR (%), CAGR (%), 2019-2030
Table 5.1 Leading Gene Therapy Drugs by Revenue ($bn), 2019
Table 5.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2019-2030
Table 5.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2019
Table 5.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2019
Table 5.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2019
Table 5.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2019
Table 5.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2019
Table 5.8 Global Gene Therapy Clinical Trials by Indication, 2019
Table 5.9 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2019
Table 5.10 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2019
Table 5.11 Global Gene Therapy Market: Revenue ($bn) and Market Shares (%) by Indication, 2019
Table 5.12 Global Market Forecast for Cancer Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.13 Rare Diseases Gene Therapy Pipeline, 2019
Table 5.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.15 Cardiovascular Gene Therapy Pipeline, 2019
Table 5.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.17 Preclinical Ophthalmologic Pipeline, 2019
Table 5.18 Clinical Ophthalmologic Pipeline, 2019
Table 5.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2019
Table 5.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2019-2030
Table 5.21 Preclinical Infectious Diseases Pipeline, 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook